Japanese company profile · 7096
StemCell Institute Inc.
English company name recorded in Japan's EDINET filer data.
Original Japanese company name: 株式会社ステムセル研究所
Name follows the English name recorded in EDINET filer data. English company name source
FY2025 · fiscal year ended March 2026Latest filing date: 2026-06-23What does this company do?
What does this company do?
In its FY2025 public filing, StemCell Institute Inc. reports Cell banks. The page shows business-level revenue and profit where the source disclosures support comparison.
StemCell Institute Inc.'s largest reported business by revenue in FY2025 was Cell banks.
The business with the highest reported segment profit in FY2025 was Cell banks.
FY2025 · fiscal year ended March 2026 · View original filing ↗ The source document may be in Japanese.
Reported company-wide figures
- Company revenue
- ¥2.81B ↗ FY2025 · fiscal year ended March 2026
- Operating profit
- ¥202.66M ↗ FY2025 · fiscal year ended March 2026
- Comparable margin
- 7.2% ↗ FY2025 · fiscal year ended March 2026
JGAAP · Consolidated company-wide
Company profile
Identity
- Securities code
- 7096
- EDINET code
- E35563
- Corporate number
- 8010401038548
- Listing status
- Listed
- Industry (EDINET filer classification)
- Pharmaceuticals
Location and fiscal year
- Headquarters
- 東京都港区 · As filed in Japanese
- Fiscal year end
- 3month
- Latest fiscal year
- FY2025
- Accounting standard
- JGAAP
- P16 data snapshot
- 2026-11-07
Company size
- Employees (consolidated)
- 136 people (FY2025)
- Employees (non-consolidated)
- 120 people (FY2025)
- Capital stock
- JPY 704.8 million (FY2025)
Official information
- Latest annual securities report
- Latest annual securities report Opens in a new tab
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
How does it make money?
Revenue leader and profit leader
Cell banks
| Business | Sales | Share of company sales | Operating profit | Margin |
|---|---|---|---|---|
| Cell banks | ¥2.81B ↗ | — | ¥202.66M ↗ | 7.2% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Company-wide trend
Company revenue
JGAAP · Consolidated- FY2025
100.0 ¥2.81B
Company revenue
JGAAP · Parent-only- FY2021
66.5 ¥1.78B - FY2022
78.1 ¥2.09B - FY2023
92.6 ¥2.48B - FY2024
100.0 ¥2.68B
Company operating profit
JGAAP · Consolidated- FY2025
100.0 ¥202.66M
Company operating profit
JGAAP · Parent-only- FY2021
54.2 ¥226.95M - FY2022
71.1 ¥297.56M - FY2023
98.9 ¥413.76M - FY2024
100.0 ¥418.51M
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
Company profile
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
- Growth—No comparable data
- ProfitabilityPosition among all companies with available values in the fixed reference data.FY2025
59 - Business concentration—No comparable data
- Business change—No comparable data
- Cash generation—No comparable data
- Growth persistencePeer-position scoreFY2021→FY2022, FY2022→FY2023, FY2023→FY2024
79
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YI32
View original filing ↗